AccessHope and Emory Healthcare collaboration will extend cancer expertise in Southeast and beyond

Jan. 11, 2022

Media Contact

Christina Khoury-Folkens

Janet Christenbury

Emory Healthcare, together with Winship Cancer Institute of Emory University, joins existing collaboration among three other National Cancer Institute (NCI)-Designated Comprehensive Cancer Centers to enable nationwide remote delivery of expertise for employers, cancer patients and their treating oncologists.
Specialists from Winship will provide expert cancer support for AccessHope’s employer health plans, plan members and their treating oncologists in the Southeastern U.S.
AccessHope addresses high market demand for remote cancer support services from NCI-Designated Comprehensive Cancer Centers such as Winship.

DUARTE, CALIFORNIA, and ATLANTA — AccessHope, LLC, a company that provides cancer expertise to employers and their health care affiliates, today announced a new foundational collaboration with Emory Healthcare and Winship Cancer Institute of Emory University, extending access to specialized cancer expertise to more people living with complex cancers across the United States.

Emory Healthcare, along with Winship, joins AccessHope’s existing collaboration with three other National Cancer Institute (NCI)-Designated Comprehensive Cancer Centers to offer innovative support and deliver advanced, expert knowledge for employees with cancer to their health plans and their local treating oncologists.

Cancer specialists from Winship will provide tumor type-specific expertise for AccessHope’s core services — accountable precision oncology, expert advisory review and cancer support team — to plan members in southeastern states, including Alabama, Florida, Georgia, Mississippi, North Carolina, South Carolina and Tennessee, and across the United States.

“People deserve access to the latest cancer care knowledge, regardless of their geographic location. The ability to remotely access health information has become increasingly important for the patient experience, particularly during the COVID-19 pandemic when people’s ability or willingness to travel for cancer care may have been impacted,” says Mark Stadler, chief executive officer of AccessHope.

Through an employer benefit that provides access to a broad network of oncology experts, AccessHope’s cancer support services help employees and their families navigate the complexity of a cancer diagnosis to improve quality of life and health outcomes, return to their work and lives, and reduce expenses.

Medical specialists at Emory Healthcare and Winship are at the forefront of lifesaving discoveries and the latest cancer research, and they can help health plans and treating oncologists guide their patients to clinical trials, genetic/genomic testing and the newest personalized treatments, such as breakthrough medications and targeted therapies.

“We are honored to welcome Emory Healthcare and Winship into our growing family of foundational collaborators, which also includes City of Hope, Dana-Farber Cancer Institute and Northwestern Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,” adds Stadler. “As we continue connecting plan members and their local treating oncologists with these world-renowned specialists who can review their cases, our primary goal is to share insights they can use to optimize cancer treatment plans and improve clinical outcomes.”

Emory Healthcare, with 24,000 employees and 11 hospital campuses, is the most comprehensive academic health system in Georgia. System-wide, it has 2,722 licensed beds and more than 3,300 physicians practicing in more than 70 specialties, serving metro Atlanta and the state of Georgia with 250 locations.

“At Emory Healthcare, patients are at the center of everything we do, and our mission is to improve lives and provide hope,” says Jonathan S. Lewin, MD, executive vice president for health affairs of Emory University and chief executive officer of Emory Healthcare. “Through innovation and discovery, our clinicians and cancer specialists are focused on advancing medical research and progressive cancer treatments that will benefit those who are diagnosed, and we are pleased to collaborate with AccessHope to provide further access to patients in need of cancer expertise.”

Winship Cancer Institute expertise available for patients with complex cancers

As Georgia’s only NCI-Designated Comprehensive Cancer Center, Winship is the epicenter of the state’s cancer research, education and care and is ranked in the top 50 in the United States and No. 1 in Georgia for cancer care, according to U.S. News & World Report. Winship clinicians see more than 17,000 newly diagnosed patients each year. The center is poised to grow; construction is underway on a new 17-story cancer facility, the largest expansion in Winship’s history.

“Winship is proud to work with AccessHope to provide top-notch expertise to the care of patients in our region at an exciting time of new possibilities in cancer care,” says Winship Executive Director Suresh S. Ramalingam, MD. “Winship’s leading experts will work with individuals’ health plans and their local care teams to provide specialized knowledge and insights.”

Research is also a key component of Winship’s mission. Investigators enrolled more than 900 participants in more than 300 clinical trials in 2020, the same year it received $80 million in research funding. Winship collaborates with professionals from around the world and with national and state agencies, including the Centers for Disease Control and Prevention, the American Cancer Society and the Georgia Research Alliance.

“Winship oncologists are seeing a recent trend of more patients coming through our doors with advanced or later-stage cancers, which likely progressed from delayed screenings or treatment during the COVID-19 pandemic,” says Sagar Lonial, MD, FACP, chief medical officer of Winship Cancer Institute of Emory University. “Through our new collaboration with AccessHope, Winship clinicians will provide valuable medical expertise for patients with complex cancers, including our multidisciplinary teams that care for head and neck, lung, prostate and breast cancers as well as the rapidly changing field of blood cancers. Those experts can then provide recommendations to local oncologists, so individuals then receive state-of-the-art care as quickly as possible.”

Increased quality and access to health care

Emory Healthcare was named as one of the top 10 most trusted health care brands in the United States and the top health care system in Georgia in a recent survey conducted by the American Hospital Association of more than 30,000 consumers. Consumers reported that three strategies were paramount to boost trust: being transparent and clear with information, listening and being empathetic, and offering care and treatment choices to patients.

“Improving access, increasing options and expanding health literacy can go a long way in addressing critical issues in health care such as health disparities, trust in health care and health care providers, and patients proactively seeking out specialized medical care. AccessHope’s unique approach in connecting people with cancer expertise, regardless of their geographic location, was a natural fit for Emory Healthcare and Winship Cancer Institute, where patients come first,” says Dane Peterson, president and chief operating officer of Emory Healthcare. “Together, Emory Healthcare and AccessHope will increase access to medical expertise, and we will further transform health and healing at home in Georgia and beyond.”

In December 2021, the medical journal JCO Oncology Practice published a peer-reviewed study on how AccessHope influences lung cancer cases. Titled “A Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience During a Pandemic,” the study found that AccessHope’s NCI-level subspecialists provided evidence-based recommendations to influence 93% of the cases AccessHope received. Accompanying the clinical and humanistic benefits was an average of $19,000 in cost savings per plan member.

Today, AccessHope serves approximately 3.3 million plan members who have access to its cancer support services through 75 employers and collaborative relationships with Collective Health via its Premier Partner Program and with Health Transformation Alliance and Quantum Health.

About AccessHope

AccessHope, LLC, believes in putting the ever-growing body of cancer knowledge to work for the greater good. The company delivers a revolutionary cancer benefit that connects employees with cancer to the latest cancer knowledge from City of Hope, Dana-Farber Cancer Institute, Emory Healthcare and Winship Cancer Institute of Emory University, and Northwestern Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, accessing the expertise of National Cancer Institute-Designated Comprehensive Cancer Centers. AccessHope is sharing the latest discoveries in cancer care and working with local oncologists to help as they develop precise plans for treatment. The company brings the vast expertise of major medical centers to people near and far. They never have to switch doctors. They never have to leave home. It’s simply a better approach to cancer. And getting better every day. A subsidiary of City of Hope, a world-renowned independent cancer research and treatment organization, AccessHope offers the benefit to approximately 3.3 million members through 75 employers, including 32 Fortune 1000 companies. For more information about AccessHope, visit myaccesshope.org and follow us on LinkedIn and Twitter.

About Emory Healthcare

Emory Healthcare, with 24,000 employees and 11 hospital campuses, is the most comprehensive academic health system in Georgia. System-wide, it has 2,722 licensed beds, more than 3,300 physicians practicing in more than 70 specialties, serving metro Atlanta with 250 locations. It also provides services to greater Georgia through a joint venture at St. Francis–Emory Healthcare Hospital in Columbus, 10 regional affiliate hospitals, and its clinically integrated physician network. For more information, visit emoryhealthcare.org.

About Winship Cancer Institute of Emory University

As the only NCI-Designated Comprehensive Cancer Center for the state of Georgia, Winship Cancer Institute of Emory University discovers, develops and delivers some of the world's most effective ways to prevent, detect, diagnose and treat each patient's unique cancer. Winship leverages the depth and breadth of Emory University and collaborates with other NCI-Designated Comprehensive Cancer Centers and leading cancer organizations. Winship has more than 500 faculty members who together received $80 million in cancer research funding in 2020, $33 million of that from NCI. Also, in 2020, Winship enrolled more than 900 people in its 300 cancer clinical trials. For more information, visit Winship Cancer Institute of Emory University.

Recent News

By downloading Emory news media, you agree to the following terms of use:

Creative Commons Attribution-NoDerivatives 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NoDerivatives 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 – Definitions.

Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.
Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.
Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.
Licensor means the individual(s) or entity(ies) granting rights under this Public License.
Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 – Scope.

License grant.
1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
  1. reproduce and Share the Licensed Material, in whole or in part; and
  2. produce and reproduce, but not Share, Adapted Material.
2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
3. Term. The term of this Public License is specified in Section 6(a).
4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
5. Downstream recipients.
  1. Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
  2. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
Other rights.
1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
2. Patent and trademark rights are not licensed under this Public License.
3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.

Section 3 – License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

Attribution.
1. If You Share the Licensed Material, You must:
  1. retain the following if it is supplied by the Licensor with the Licensed Material:
    1. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
    2. a copyright notice;
    3. a notice that refers to this Public License;
    4. a notice that refers to the disclaimer of warranties;
    5. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
  2. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
  3. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
  For the avoidance of doubt, You do not have permission under this Public License to Share Adapted Material.
2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

Section 4 – Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database, provided You do not Share Adapted Material;
if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and
You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 – Disclaimer of Warranties and Limitation of Liability.

Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.
To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.

The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 – Term and Termination.

This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or
2. upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 – Other Terms and Conditions.

The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 – Interpretation.

For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark “Creative Commons” or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.